S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
New York lawmakers pass $237 billion budget with policies to jump-start housing market

Lyell Immunopharma (LYEL) Competitors

$2.23
-0.10 (-4.29%)
(As of 04/19/2024 ET)

LYEL vs. OLMA, CALT, KRRO, ATXS, SLN, MLYS, SIGA, ZYME, ALXO, and YMAB

Should you be buying Lyell Immunopharma stock or one of its competitors? The main competitors of Lyell Immunopharma include Olema Pharmaceuticals (OLMA), Calliditas Therapeutics AB (publ) (CALT), Korro Bio (KRRO), Astria Therapeutics (ATXS), Silence Therapeutics (SLN), Mineralys Therapeutics (MLYS), SIGA Technologies (SIGA), Zymeworks (ZYME), ALX Oncology (ALXO), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "pharmaceutical preparations" industry.

Lyell Immunopharma vs.

Lyell Immunopharma (NASDAQ:LYEL) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership, community ranking and earnings.

Lyell Immunopharma has a beta of -0.56, indicating that its share price is 156% less volatile than the S&P 500. Comparatively, Olema Pharmaceuticals has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500.

Olema Pharmaceuticals has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -180,486.14%. Lyell Immunopharma's return on equity of -32.67% beat Olema Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Lyell Immunopharma-180,486.14% -32.67% -28.78%
Olema Pharmaceuticals N/A -44.67%-40.99%

Olema Pharmaceuticals has lower revenue, but higher earnings than Lyell Immunopharma. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lyell Immunopharma$130K4,358.79-$234.63M-$0.93-2.40
Olema PharmaceuticalsN/AN/A-$96.65M-$2.16-4.60

66.1% of Lyell Immunopharma shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 24.0% of Lyell Immunopharma shares are owned by company insiders. Comparatively, 23.5% of Olema Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Lyell Immunopharma currently has a consensus target price of $5.50, suggesting a potential upside of 146.64%. Olema Pharmaceuticals has a consensus target price of $21.43, suggesting a potential upside of 115.80%. Given Lyell Immunopharma's higher possible upside, research analysts plainly believe Lyell Immunopharma is more favorable than Olema Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lyell Immunopharma
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
Olema Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
3.00

Olema Pharmaceuticals received 10 more outperform votes than Lyell Immunopharma when rated by MarketBeat users. Likewise, 59.46% of users gave Olema Pharmaceuticals an outperform vote while only 54.55% of users gave Lyell Immunopharma an outperform vote.

CompanyUnderperformOutperform
Lyell ImmunopharmaOutperform Votes
12
54.55%
Underperform Votes
10
45.45%
Olema PharmaceuticalsOutperform Votes
22
59.46%
Underperform Votes
15
40.54%

In the previous week, Lyell Immunopharma had 1 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 4 mentions for Lyell Immunopharma and 3 mentions for Olema Pharmaceuticals. Lyell Immunopharma's average media sentiment score of 0.54 beat Olema Pharmaceuticals' score of 0.34 indicating that Lyell Immunopharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lyell Immunopharma
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Olema Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Lyell Immunopharma beats Olema Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LYEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LYEL vs. The Competition

MetricLyell ImmunopharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$566.63M$6.39B$4.89B$7.32B
Dividend YieldN/A3.10%2.93%3.96%
P/E Ratio-2.406.36146.0314.69
Price / Sales4,358.79306.062,467.5282.00
Price / CashN/A28.9747.3134.38
Price / Book0.865.324.564.15
Net Income-$234.63M$139.72M$104.37M$214.00M
7 Day Performance-25.91%-6.71%-4.52%-3.51%
1 Month Performance9.31%-9.67%-6.80%-6.05%
1 Year Performance-3.46%-6.54%6.60%3.98%

Lyell Immunopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OLMA
Olema Pharmaceuticals
1.8123 of 5 stars
$11.53
+2.3%
$21.43
+85.9%
+141.0%$644.76MN/A-5.3474News Coverage
CALT
Calliditas Therapeutics AB (publ)
2.8297 of 5 stars
$21.73
+1.0%
$34.00
+56.5%
-21.4%$647.34M$113.78M-13.25192News Coverage
KRRO
Korro Bio
2.3593 of 5 stars
$78.69
+7.1%
$126.25
+60.4%
N/A$631.09M$14.07M-0.8395News Coverage
ATXS
Astria Therapeutics
1.5577 of 5 stars
$11.49
+0.8%
$21.75
+89.3%
-10.8%$630.80MN/A-4.9159Positive News
SLN
Silence Therapeutics
2.0879 of 5 stars
$21.00
-1.9%
$57.25
+172.6%
+283.7%$628.53M$31.55M-14.38109
MLYS
Mineralys Therapeutics
1.9283 of 5 stars
$13.14
-0.9%
$33.50
+154.9%
-18.0%$652.14MN/A-6.5728Positive News
SIGA
SIGA Technologies
0.6474 of 5 stars
$9.27
+3.0%
N/A+41.4%$659.00M$139.92M9.7645Options Volume
ZYME
Zymeworks
0.8677 of 5 stars
$9.36
-2.7%
$15.00
+60.3%
-10.0%$660.54M$76.01M-5.38272News Coverage
ALXO
ALX Oncology
1.4569 of 5 stars
$12.34
+1.6%
$18.42
+49.2%
+212.0%$618.85MN/A-3.2972Insider Selling
News Coverage
YMAB
Y-mAbs Therapeutics
0.3296 of 5 stars
$14.07
-2.6%
$16.57
+17.8%
+160.0%$615.99M$84.82M-28.71100News Coverage

Related Companies and Tools

This page (NASDAQ:LYEL) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners